English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsIxempra

    Ixempra

    Jump to
    • BDR Pharma lines up more compulsory licences: Sources

      BDR Pharma lines up more compulsory licences: Sources

      Indian generic drug maker BDR Pharma's plans could draw new battles lines over intellectual property rights. After seeking a compulsory license for leukemia drug Sprycel, BDR Pharma is setting its sight on more patent-protected anti-cancer drugs, reports CNBC-TV18's Archana Shukla.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347